“Novartis snaps up first in class antibiotic” (PharmaTimes)
Swiss giant Novartis has snapped up the rights to market a potentially first-in-class antibiotic from Paratek Pharmaceuticals for an undisclosed sum, bolstering the company’s armamentarium in this field following its acquisition of Protez Pharmaceuticals in June last year.
Nyloxin Rx is a prescription pain reliever produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating Stage 3 pain, which is the most severe pain that inhibits one’s ability to fully function. Additionally, Nyloxin Rx does not rely on the use of opioids for its pain relieving action, but, instead, uses a novel mechanism from cobra venom peptides for treating pain.
“APP Pharmaceuticals Receives FDA Approval for Sumatriptan Succinate Injection” (Therapeutics Daily)
US-based pharmaceutical company APP Pharmaceuticals Inc, a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals HoldingInc (NASDAQ: APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market Sumatriptan Succinate Injection, USP, in two dosage strengths.
“Ingredient Supplier for Labopharm Drug Resolves Manufacturing Issues with FDA” (Therapeutics Daily)
An ingredient supplier for a new drug developed by Labopharm Inc. (TSX:DDS) has resolved manufacturing issues it had with the U.S. Food and Drug Administration, making it possible for the Quebec drug maker to proceed with a regulatory product review south of the border.
“Gardasil Not Cost Effective In Boys” (VisitBulgaria.com)
According to US researchers, vaccinating boys against cervical cancer and genital warts virus does not appear to be cost-effective, as assuming all girls are given the shot, giving the boys the same may not be worth the expense.
SUBSCRIBE